Every material Form 8-K Modular Medical, Inc. has filed with the SEC since May 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Modular Medical director Duane DeSisto resigned from the board effective immediately on October 26, 2026, and the company said the resignation was not due to a disagreement over its operations, policies or practices. At the October 23, 2026 annual meeting, shareholders re-elected the board slate, approved a 2,500,000-share increase to the equity incentive plan, and ratified Farber Hass Hurley LLP as auditor for the fiscal year ending March 31, 2027.
Duane DeSisto resigned from the board on October 26, 2026, effective immediately, with no disagreement cited.
Approximately 65% of outstanding common shares were represented at the October 23, 2026 annual meeting.
Shareholders approved the equity incentive plan amendment, with 2,294,200 votes for and 811,943 against.
Shareholders ratified Farber Hass Hurley LLP with 6,171,976 votes for and 15,512 against.
Modular Medical said directors Jeffrey Goldberg and Carmen Volkart will not stand for re-election when their current terms expire at the fiscal 2027 annual meeting of shareholders. Both said the decisions were not due to any disagreement with the company on operations, policies or practices.
Jeffrey Goldberg gave notice on September 25, 2026 that he will not seek re-election.
Carmen Volkart notified the nominating and governance committee chair on September 24, 2026 of her decision.
Both terms expire at the fiscal 2027 annual meeting of shareholders.
The filing states neither departure resulted from a disagreement with the company.
Modular Medical's board awarded stock options on May 14, 2026 to Chairman, President, CFO and Treasurer Paul DiPerna and to COO Kevin Schmid, at an exercise price of $3.46 per share. The filing describes routine equity compensation under the company's 2017 Equity Incentive Plan, with no change in officer roles disclosed, and its effect on shareholders depends on how many shares are eventually issued.
Board awarded 11,218 stock options to Paul DiPerna and 4,674 stock options to Kevin Schmid on May 14, 2026.
Exercise price is $3.46 per share; options expire May 14, 2036.
One-third of each award vests May 14, 2027, with the remainder vesting monthly in 1/24th increments thereafter, subject to continued service.
Awards were made under the Amended and Restated 2017 Equity Incentive Plan, as amended.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Modular Medical, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →